Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform

Clinica Chimica Acta

Volumn 411, Issue 23-24, 2010, Pages 2097-2100

  Qian, Jun ^a   Lin, Jiang ^a   Yao, Dong Ming ^a   Chen, Qin ^a   Xiao, Gao Fei ^a   Ji, Run Bi ^a   Li, Yun ^a   Yang, Jing ^a   Qian, Zhen ^a  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

High resolution melting analysis; JAK2 V617F; LightScanner; Mutation; Myeloproliferative neoplasm

Indexed keywords

JANUS KINASE 2;

ACCURACY; ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; CANCER SCREENING; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HIGH RESOLUTION MELTING ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; MYELOPROLIFERATIVE DISORDER; MYELOPROLIFERATIVE NEOPLASM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RELIABILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS;

DNA MUTATIONAL ANALYSIS; HUMANS; JANUS KINASE 2; MUTATION; MYELOPROLIFERATIVE DISORDERS; TIME FACTORS; TRANSITION TEMPERATURE;

EID: 77957752388     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.08.020     Document Type: Article

References (31)

1. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet 2005, 365:1054-1061.
2. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
3. Vainchenker W., Constantinescu S.N. A unique activating mutation in JAK2(V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology 2005, 2005:195-200.
4. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005, 280:22788-22792.
5. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005, 434:1144-1148.
6. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
7. Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005, 106:2162-2168.
8. Kr̈oger N., Badbaran A., Holler E., et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109:1316-1321.
9. Tefferi A., Thiele J., Orazi A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110:1092-1097.
10. Vardiman J.W., Bennett J.M., Bain B.J., et al. Myelodysplastic/myeloproliferative neoplasm, unclassifiable. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 85-86. IARC Press, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
11. Lippert E., Boissinot M., Kralovics R., et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006, 108:1865-1867.
12. Steensma D.P. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006, 8:397-411.
13. Wittwer C.T., Reed G.H., Gundry C.N., Vandersteen J.G., Pryor R.J. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 2003, 49:853-860.
14. Herrmann M.G., Durtschi J.D., Bromley L.K., Wittwer C.T., Voelkerding K.V. Amplicon DNA melting analysis for mutation scanning and genotyping: cross-platform comparison of instruments and dyes. Clin Chem 2006, 52:494-503.
15. Poláková K.M., Lopotová T., Klamová H., Moravcová J. High Resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain. Leuk Res 2008, 32:1236-1243.
16. van der Stoep N., van Paridon C.D., et al. Diagnostic guidelines for high-resolution melting curve (HRM) analysis: an interlaboratory validation of BRCA1 mutation scanning using the 96-well LightScanner. Hum Mutat 2009, 30:899-909.
17. Lay M., Mariappan R., Gotlib J., et al. Detection of the JAK2 V617F mutation by LightCycler PCR and probe dissociation analysis. J Mol Diagn 2006, 8:330-334.
18. Sutton B.C., Allen R.A., Zhao Z.J., Dunn S.T. Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark 2007, 3:315-324.
19. Rapado I., Grande S., Albizua E., et al. High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. J Mol Diagn 2009, 11:155-161.
20. Er T.K., Lin S.F., Chang J.G., et al. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation. Clin Chim Acta 2009, 408:39-44.
21. Ugo V., Tondeur S., Menot M.L., et al. Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. PLoS ONE 2010, 5:e8893.
22. Boyd E.M., Bench A.J., Goday-Fernández A., et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol 2010, 149:250-257.
23. Seipp M.T., Durtschi J.D., Liew M.A., et al. Unlabeled oligonucleotides as internal temperature controls for genotyping by amplicon melting. J Mol Diagn 2007, 9:284-289.
24. Frantz C., Sekora D., Henley D.C., et al. Comparative evaluation of three JAK2V617F mutation detection methods. Am J Clin Pathol 2007, 128:865-874.
25. Tan A.Y., Westerman D.A., Dobrovic A. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation. Am J Clin Pathol 2007, 127:977-981.
26. Jelinek J., Oki Y., Gharibyan V., et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005, 106:3370-3373.
27. Vannucchi A.M., Pancrazzi A., Bogani C., Antonioli E., Guglielmelli P. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 2006, 20:1055-1060.
28. Murugesan G., Aboudola S., Szpurka H., et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol 2006, 125:625-633.
29. Poodt J., Fijnheer R., Walsh I.B., Hermans M.H. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood. Hematol Oncol 2006, 24:227-233.
30. Kröger N., Badbaran A., Holler E., et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109:1316-1321.
31. Merker J.D., Jones C.D., Oh S.T., Schrijver I., Gotlib J., Zehnder J.L. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. J Mol Diagn 2010, 12:58-64.